Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of the novel Biopump™ technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Andrew L. Pearlman, Ph.D., the Company’s President and CEO, will present a corporate overview at the 11 th Annual Israeli Life Sciences Industry Biomed 2011 Conference taking place at the David Intercontinental Hotel in Tel Aviv, Israel from May 21-23, 2012. Dr. Pearlman will deliver the Company’s presentation on Monday, May 21 at 4:30 p.m. (local time) in Hall C. ILSI-Biomed 2012 follows the success of its previous annual conferences: last year’s event drew 6,000 industry professionals, engineers and scientists, with 1,000 participants from 42 countries and more than 2,500 one-on-one meetings. This provides Medgenics with significant opportunity to showcase before a global audience of relevant industry leaders its novel, tissue-based technology platform, the Biopump, for the sustained production and dosing of therapeutic proteins using a patient’s own tissue. About Israeli Life Sciences Industry The Israel Life Science Industry (ILSI) is composed of medical device, biotechnology, pharmaceutical and medical service companies, universities and private research institutions, and providers of services to the industry such as venture capitalists, lawyers, accountants and incubators. The goal of ILSI is to develop solid information about the medical research and manufacturing community in Israel, and to make that information available to political leaders, the news media, venture capitalists, investment bankers, and the public. It is exactly this information required by potential investors be it strategic corporate players or financial investors worldwide. The intent is to demonstrate that medical research and manufacturing is a major contributor to Israel’s economy - with unusually great potential for financial growth and job creation. About Medgenics Medgenics is developing and commercializing Biopump™, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own dermal skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis and hemophilia, among others. Medgenics believes this approach has multiple benefits compared with current treatments, which include regular and costly injections of therapeutic proteins.
Medgenics has three long-acting protein therapy products in development based on this technology:
- EPODURE™ to produce and deliver erythropoietin for many months from a single administration, has demonstrated elevation and stabilization of hemoglobin levels in anemic patients for six to more than 36 months in a Phase I/II dose-ranging trial, and has received approval of a Phase IIa trial in dialysis patients due to launch in Q2 2012 in Israel. An Investigational New Drug application has been cleared by the FDA to initiate a Phase IIb study to evaluate the safety and efficacy of EPODURE in the treatment of anemia in dialysis patients in the U.S.
- INFRADURE™ for sustained production and delivery of interferon-alpha for use in the treatment of hepatitis is awaiting final approval of two Phase I/II trials in Israel in hepatitis C, slated to commence in Q3 2012, and is filed for Orphan Drug Designation with the FDA to treat hepatitis D.
- HEMODURE™ for sustained production and delivery of clotting Factor VIII therapy for the sustained prophylactic treatment of hemophilia is now in development.